Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.

Merging Business Network-Business leaders in global agreement

In the run-up to and aftermath of its $66bn acquisition of agriculture giant Monsanto, Bayer AG consistently has maintained that it has no plans to get out of the pharmaceuticals business and the German conglomerate used an investor presentation Sept. 20 to underline the point, presenting an optimistic take on both the peak earnings potential of five recently launched products as well as the promise of six Phase II or Phase III pipeline assets.

During a meet-the-management event in Cologne, Germany, Bayer CEO Werner Baumann explained the rationale behind the Monsanto acquisition, which will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.